COMP <GO>
CTKB vs PACB // EV/EBITDA & P/E VALUATION
Cytek Biosciences Inc. (NASDAQ) VS. Pacific Biosciences of California Inc. (NASDAQ) • 15-METRIC TALLY: CTKB 6
— PACB 1
■ METRIC PARITY
LAST: $6.30 (+2.61%) • MKT CAP: $818.9M
valuation
—
LAST: $2.90 (+2.47%) • MKT CAP: $901.4M
valuation
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (CTKB VS. PACB)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | CTKB | PACB | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 51.80% | 28.60% | +23.20 | CTKB | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -12.70% | -35.00% | +22.30 | CTKB | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -1.07% | -12.64% | +11.57 | CTKB | /fcf-yield <GO> |
| Operating Margin | -20.00% | -60.00% | +40.00 | CTKB | /operating-margins <GO> |
| Net Profit Margin | -33.00% | -60.00% | +27.00 | CTKB | /net-margins <GO> |
| Revenue Growth (YoY) | 0.50% | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 4.76 | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 3/9 | 3/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 65.6 | 61.4 | +4.25 | CTKB | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $818.9M | $901.4M | -$82.5M | PACB | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | CTKB REV | PACB REV | CTKB GROSS % | PACB GROSS % | CTKB FCF | PACB FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $201.5M | $160.0M | 51.8% | 28.6% | -$8.8M | -$113.9M |
| FY 2024 | $200.5M | $154.0M | 55.4% | 24.2% | $21.9M | -$212.2M |
| FY 2023 | $193.0M | $0 | — | — | $5.3M | -$259.2M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
CTKB // BETA —
PACB // BETA —